TD Cowen raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $115 from $95 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals director buys $9.0M in common stock
- Mirum Pharmaceuticals Completes Bluejay Acquisition, Expands Liver Portfolio
- Mirum Pharmaceuticals price target raised to $130 from $102 at H.C. Wainwright
- Mirum Pharmaceuticals price target raised to $101 from $94 at Evercore ISI
- Mirum Pharmaceuticals price target raised to $95 from $81 at Baird